(EMAILWIRE.COM, March 01, 2025 ) ๐๐๐ซ๐ค๐๐ญ ๐๐ฏ๐๐ซ๐ฏ๐ข๐๐ฐ:
The Global Gastroparesis Treatment Market reached US$ 7.5 billion in 2024 and is expected to grow to US$ 11.03 billion by 2033, expanding at a CAGR of 4.42% during the forecast period 2025-2033.
Gastroparesis is a chronic digestive disorder characterized by delayed stomach emptying due to impaired muscle or nerve function. Symptoms include nausea, vomiting, bloating, and early satiety, significantly affecting patients’ quality of life.
Treatment strategies focus on symptom relief and gastric motility improvement, including prokinetic medications, anti-nausea therapies, and dietary adjustments to facilitate digestion.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐ ๐ซ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐: https://www.datamintelligence.com/download-sample/gastroparesis-treatment-market
๐๐๐ซ๐ค๐๐ญ ๐๐ฒ๐ง๐๐ฆ๐ข๐๐ฌ: ๐๐ซ๐ข๐ฏ๐๐ซ๐ฌ & ๐๐๐ฌ๐ญ๐ซ๐๐ข๐ง๐ญ๐ฌ
๐๐๐ฏ๐๐ง๐๐๐ฆ๐๐ง๐ญ๐ฌ ๐ข๐ง ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐ฉ๐ญ๐ข๐จ๐ง๐ฌ
The introduction of more effective and targeted treatment solutions is fueling market growth. Prokinetic drugs, such as updated versions of metoclopramide and domperidone, continue to enhance symptom management and gastric motility.
Emerging alternative therapies, including botulinum toxin injections, offer new solutions for severe cases. Increased R&D investment supports this trend. For instance, CinDome Pharma secured $40 million in Series B financing to advance deudomperidone (CIN-102) for chronic gastroparesis, backed by investors like Perceptive Advisors and CinRx Pharma.
Improved treatment efficacy, reduced side effects, and personalized approaches are expanding market opportunities across developed and emerging regions.
๐๐๐ซ๐ค๐๐ญ ๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง:
By Gastroparesis Type: Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-surgical Gastroparesis.
By Drug Class: Prokinetic Drugs, Antiemetics, Antidepressants, Liquid Vitamin Supplements, Others.
By Route of Administration: Oral, Injectables, Others.
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
By Region: North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐จ๐ซ ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐๐ญ๐ข๐จ๐ง: https://www.datamintelligence.com/customize/gastroparesis-treatment-market
๐๐๐จ๐ ๐ซ๐๐ฉ๐ก๐ข๐๐๐ฅ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ:
๐๐จ๐ซ๐ญ๐ก ๐๐ฆ๐๐ซ๐ข๐๐ ๐๐จ๐ฅ๐๐ฌ ๐ ๐๐ข๐ ๐ง๐ข๐๐ข๐๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ ๐๐ก๐๐ซ๐
North America is expected to lead the gastroparesis treatment market, supported by:
High prevalence of diabetes and neurological disorders, key gastroparesis risk factors.
Advanced healthcare infrastructure, facilitating early diagnosis and innovative treatments.
Presence of major pharmaceutical companies engaged in research and development of novel therapies.
For instance, in October 2023, Avenacy launched thirteen injectable products in the U.S. market, including Metoclopramide Injection, USP in specialized packaging for accurate medication selection.
The cost-effectiveness and accessibility of prokinetic drugs, compared to invasive treatments, further drive market growth in the region.
๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฏ๐ ๐๐๐ง๐๐ฌ๐๐๐ฉ๐:
Key players in the global gastroparesis treatment market include:
Conmed Corporation
The Cooper Companies Inc.
Teleflex Incorporated
Medtronic Plc
B. Braun Medical Inc.
Johnson & Johnson
Laprosurge
Purple Surgical
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Peters Surgical
๐๐๐ฒ ๐๐๐ฏ๐๐ฅ๐จ๐ฉ๐ฆ๐๐ง๐ญ๐ฌ:
June 2024 ย Renexxion Ireland Ltd. received FDA clearance for its Investigational New Drug (IND) application for naronapride, an oral prokinetic agent targeting gastroparesis treatment. Naronapride acts through 5-HT4 receptor agonism and D2 receptor antagonism, positioning it as a potential best-in-class therapy.
